Peregrine Pharmaceuticals regains full complaince with NASDAQ
Peregrine Pharmaceuticals announced that on November 3, the Company received notice from the NASDAQ Market Listing Qualifications Department stating that it has regained compliance with the minimum bid price rule for the continued listing of its common stock on the NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 5550(a)(2). :theflyonthewall.com
News For PPHM From The Last 14 Days
Check below for free stories on PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
